Is Zytiga with Prednisone Effective in Men with Metastatic Prostate Cancer Who Have Visceral Disease?

Castate resistant metastatic prostate cancer (mRPC) withvisceral disease (tumors involving the internal organs of the body, specifically those within the chest (as the heart or lungs) or abdomen (as the liver, pancreas or intestines) is a negative prognostic factor. In many cases clinical trials of new investigational drugs rule out men with visceral disease from [...]

Prostate Cancer Comes In Many Flavors, Some Rare, Hard to Diagnosis and Aggressive

Prostate cancer is not just one disease; in reality there are several different types of prostate cancer, which will look different under a microscope and behave differently in your body.  In addition to the more common types of prostate cancer there are also several kinds of rare cancers that can develop in the prostate. Prostate [...]

To Stay Alive Avoid the Hospital on Weekends and Night Time If Possible

In prior posts I have strongly recommended that, if possible, it is in your best interest not to go into the hospital in the month of July. The month of July is the traditional beginning of a new rotation for the new hospital Residents, or there are an overwhelming number of newly minted doctors with [...]

Positive Results for Xtandi in the Pre-Chemotherapy Space

It was announced today that after observing significant benefits in overall survival (OS) and radiographic progression free survival (PFS) ,the two co-primary endpoints of the the Xtandi pre-chemotherapy trial,  the Independent Data Monitoring Committee (IDMC) for The Phase 3 PREVAIL trial of enzalutamide in metastatic prostate cancer recommends that "the study be stopped and patients [...]

Ethical Lapse After Ethical Lapse in Medical Research- The American Story

Last Thursday’s New York Times had an article about Dr. Perry Hudson, in 1950s a medical researcher at Columbia University.  The article was about his research on skid row in New York City where he offered alcoholics in lower Manhattan an offer: If they agreed to surgical biopsies of their prostates, they would get a [...]

By |2017-10-19T10:49:22-04:00October 21st, 2013|Advanced Prostate Cancer, ethics, Research, Uncategorized|0 Comments

Step Therapy – The Creeping Crud Infecting Our Care Takes Another Bite Out Of Our Treatment  

Step therapy (ST) has again reared its most ugly head in our prostate cancer world, to the detriment of us, prostate cancer survivors and only to the benefit of private insurance payers. So, what is this “creeping crud,” Step Therapy (aka as Fail First Therapy)? Simply, ST is when insurance companies decide, without sound medical [...]

WHAT – Fired By Your Doctor! Sounds Like You Are Lucky

I want to share a post I made today on the advanced prostate cancer online support group ).  It was in response to an ongoing thread with a spouse (caregiver) who was fired by her husband's doctor by having his nurse call them.  She was guilty of asking questions, relevant and important ones, but the [...]

Medicare Open Enrollment Begins Today

All of the Americans who receive their insurance benefits from Medicare need to become aware that the Medicare Open Enrollment Period begins today,   October 15. What is the Medicare open enrollment period?During this open enrollment period you can make new choices and pick plans that work best for you depending upon your doctors and [...]

61 Years Young & 67 Years Old – One We keep and the Other Is To Be Discarded!

We are now around half way through the month of October, I am sorry breast cancer awareness month, I keep forgetting!  How can I forget with that pink ribbon on everything I buy at the supermarket and after watching the manliest of men, football players, dancing around with pink sneakers. So, why is breast cancer [...]

Is Zytiga Working and When to Move on to Another Treatment? Knowing by Counting Your CTCs

At the 2013 European Cancer Congress in Amsterdam Dr. Howard Scher from Sloan Kettering Hospital reported that a panel of biomarkers could identify men with metastatic, castration-resistant prostate cancer (mCRPC) who were responding well or less well to treatment with Zytiga + prednisone (abiraterone + prednisone). Dr. Scher provided data in his presentation to support [...]

Go to Top